New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
06:31 EDTXNPT
theflyonthewall.com: XenoPort, Astellas announce submission of NDA in Japan
Astellas Pharma and XenoPort announced that a new drug application has been filed with the Pharmaceuticals and Medical Device Agency in Japan for ASP8825, also known as XP13512, as a potential treatment for restless legs syndrome. The data supporting safety and efficacy in the NDA filing comes from the successful Phase 2 study in RLS patients and long-term safety study conducted by Astellas in Japan and the RLS clinical program conducted by XenoPort in the United States. The acceptance of filing of the NDA triggers a $5 million milestone payment from Astellas to XenoPort. :theflyonthewall.com



News For XNPT From The Last 14 Days
Check below for free stories on XNPT the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2010
08:11 EDTXNPT
theflyonthewall.com: XenoPort has an FDA PDUFA Date

Subscribe for More Information :theflyonthewall.com

February 8, 2010
08:04 EDTXNPT
theflyonthewall.com: XenoPort February put volatility at 146, June at 77 into FDA deadline
XenoPort closed at $19.01. The FDA deadline for approval of XP13512 (512) in RLS (restless leg syndrome) is expected on February 9, 2010. XNPT February put option implied volatility is at 146, March puts are at 99, June puts are at 77; verses its 26-week average of 81, according to Track Data, suggesting larger near term price movement. :theflyonthewall.com

February 4, 2010
07:28 EDTXNPT
theflyonthewall.com: XenoPort February put volatility at 109, June at 62 into FDA deadline

Subscribe for More Information :theflyonthewall.com